Just listened to audio playback of 8Sep presentati
Post# of 72440
At the 2:30 mark Dr B says that because P has a 505 (b) (2) designation that the Phase III should be more expeditious than normal. Wonder how long we are talking and whether mgt will determine that it is more advantageous to pay for our own Ph III and get vastly bigger return for psoriasis definition?
He did sound so confident that B will certainly become a multi-definition drug with a whole host of other possible uses.
They have been working on the formulation so I have to think mgt knows pretty well by now whether the oral forms for both B and K are feasible and economically realistic.